Pembrolizumab in combination with chemotherapy and radiotherapy is in clinical development for the treatment of unresectable, programmed death-ligand 1 positive (PD-L1+), squamous cell oesophageal cancer. This is a type of cancer that begins in the thin, flat cells lining the food pipe (oesophagus) and may spread to other parts of the body and is untreatable by surgery. Symptoms include difficulty swallowing, persistent indigestion or heartburn, weight loss, pain in the throat, and chronic cough. In the UK it is more common in older people (≥75 years old) and males. There is a need for new treatment options, including immunot
Pembrolizumab with radiotherapy and chemotherapy for treating unresectable oesophageal cancer
Pembrolizumab in combination with chemotherapy and radiotherapy is in clinical development for the treatment of unresectable, programmed death-ligand 1 positive (PD-L1+), squamous cell oesophageal cancer. This is a type of cancer that begins in the thin, flat cells lining the food pipe (oesophagus) and may spread to other parts of the body and is untreatable by surgery.